Single shot can prevent malaria relapse

20 November 2020

British drugmaker GlaxoSmithKline (LSE: GSK) and the Medicines for Malaria Venture (MMV) have presented positive data from the TEACH study of tafenoquine.

GSK and MMV are developing the 8-aminoquinoline therapy for the prevention of relapse of malaria in children and adolescents.

The TEACH study examines the impact of a single-dose of tafenoquine, and the results show that 95% had no recurrence of P. vivax malaria during four months of follow-up, an efficacy rate which is in line with studies in adults and older adolescents.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK